Previous 10 | Next 10 |
home / stock / esaly / esaly news
Grandbrothers/iStock Editorial via Getty Images In a detailed expose, journalists at STAT have uncovered the methods Biogen (BIIB) used in gaining approval of Aduhelm (aducanumab) -- a drug that was once shelved in 2019 -- including an off-the-books meeting with a key FDA official. That offic...
Galapagos has over $6.2 billion in cash with no debt and a market capitalization of only $4.5 billion. The company has an approved product that is expected to generate €500 million annually in sales in Europe in the medium term. The partnership with biotech giant Gilead dem...
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) TOKYO, June 24, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy desig...
Biogen (BIIB) and Eisai (ESALF), (ESALY) announced that the FDA granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational humanized monoclonal antibody for Alzheimer's disease ((AD)).Breakthrough Therapy designation aimed to accelerate the research work and rev...
designer491/iStock via Getty Images Biogen (BIIB) and Eisai (ESALY) has responded to questions surrounding the controversial approval of their Alzheimer's drug Aduhelm (aducanumab).The response follows yesterday's release of internal FDA memos regarding the agency's divergent thinking about t...
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma TOKYO, June 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the...
Bet_Noire/iStock via Getty Images The fallout continues over the FDA decision to approve Aduhelm (aducanumab), the Alzheimer's disease treatment developed by Biogen (BIIB) and Eisai (ESALY). The regulator has approved the treatment amid objections raised by its drug statistics offic...
Media discussion about newly approved Alzheimer's disease treatment Aduhelm (aducanumab) has focused much attention on its high price tag and questionable efficacy. But the drug, which was developed by Biogen (NASDAQ: BIIB) in partnership with Japanese pharma Eisai (OTC: ESALY...
As the largest owner and operator of diagnostic imaging centers in the U.S., RadNet (NASDAQ: RDNT) is a one-stop-shop for medical imaging. Providing X-rays, ultrasounds, CT scans, and MRIs, the radiology company valued at $1.8 billion will likely get a boost to its growth as a resul...
Dr_Microbe/iStock via Getty Images Today's up to $3B development and commercialization deal from Bristol-Myers Squibb (BMY) for Eisai's (ESALY) for MORAb-202 is putting antibody drug conjugates ("ADCs"), which some feel is the future of cancer therapeutics, into the spotlight. The o...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...